EG23910A - Pharmaceutical formulations containing voriconazole - Google Patents

Pharmaceutical formulations containing voriconazole

Info

Publication number
EG23910A
EG23910A EG70998A EG70998A EG23910A EG 23910 A EG23910 A EG 23910A EG 70998 A EG70998 A EG 70998A EG 70998 A EG70998 A EG 70998A EG 23910 A EG23910 A EG 23910A
Authority
EG
Egypt
Prior art keywords
pharmaceutical formulations
formulations containing
containing voriconazole
voriconazole
pharmaceutical
Prior art date
Application number
EG70998A
Other languages
English (en)
Inventor
Valerie D Harding
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG23910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG23910A publication Critical patent/EG23910A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EG70998A 1997-06-21 1998-06-20 Pharmaceutical formulations containing voriconazole EG23910A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
EG23910A true EG23910A (en) 2007-12-30

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
EG70998A EG23910A (en) 1997-06-21 1998-06-20 Pharmaceutical formulations containing voriconazole

Country Status (48)

Country Link
US (1) US6632803B1 (bg)
EP (1) EP1001813B8 (bg)
JP (2) JP2000513029A (bg)
KR (1) KR100372988B1 (bg)
CN (1) CN1125653C (bg)
AP (1) AP912A (bg)
AR (1) AR015900A1 (bg)
AT (1) ATE238812T1 (bg)
AU (1) AU724799B2 (bg)
BG (1) BG64584B1 (bg)
BR (1) BRPI9809468B8 (bg)
CA (1) CA2295035C (bg)
CO (1) CO4940450A1 (bg)
CZ (1) CZ289570B6 (bg)
DE (1) DE69814091T2 (bg)
DK (1) DK1001813T3 (bg)
DZ (1) DZ2523A1 (bg)
EA (1) EA001924B1 (bg)
EG (1) EG23910A (bg)
ES (1) ES2195355T3 (bg)
GB (1) GB9713149D0 (bg)
HK (1) HK1027966A1 (bg)
HR (1) HRP980341B1 (bg)
HU (1) HU228338B1 (bg)
ID (1) ID22939A (bg)
IL (1) IL132918A (bg)
IS (1) IS2004B (bg)
MA (1) MA26508A1 (bg)
ME (1) ME00907B (bg)
MY (1) MY118151A (bg)
NO (1) NO313125B1 (bg)
NZ (1) NZ501066A (bg)
OA (1) OA11232A (bg)
PA (1) PA8453201A1 (bg)
PE (1) PE84899A1 (bg)
PL (1) PL191295B1 (bg)
PT (1) PT1001813E (bg)
RS (1) RS49633B (bg)
SA (1) SA98190159B1 (bg)
SI (1) SI1001813T1 (bg)
SK (1) SK282946B6 (bg)
TN (1) TNSN98090A1 (bg)
TR (1) TR199903191T2 (bg)
TW (1) TW406023B (bg)
UA (1) UA57083C2 (bg)
UY (1) UY25055A1 (bg)
WO (1) WO1998058677A1 (bg)
ZA (1) ZA985364B (bg)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
MX2010013363A (es) * 2008-06-06 2011-03-03 Glenmark Pharmaceuticals Ltd Formulacion topica estable contiene voriconazol.
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
WO2011020605A1 (en) 2009-08-19 2011-02-24 Ratiopharm Gmbh Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
CN107049935A (zh) 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂
EP2409699B1 (en) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
EP2720723B1 (en) 2011-06-15 2018-04-11 Synthon BV Stabilized voriconazole composition
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
US20130202681A1 (en) * 2012-01-05 2013-08-08 Frederick Timothy Guilford Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
CA2873044C (en) 2012-05-08 2021-01-26 Onyx Therapeutics, Inc. Cylodextrin complexation methods for formulating peptide proteasome inhibitors
AU2013257830A1 (en) 2012-05-11 2014-11-20 Cipla Limited Pharmaceutical composition
EP2943224B1 (en) 2013-01-11 2020-01-01 Xellia Pharmaceuticals ApS Voriconazole inclusion complexes
CA2904670A1 (en) 2013-03-14 2014-09-13 Fresenius Kabi Usa, Llc Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US11040958B2 (en) 2017-02-17 2021-06-22 Wuhan Ll Science And Technology Development Co., Ltd. Triazole antimicrobial derivative, pharmaceutical composition and use thereof
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2002332234A (ja) 2002-11-22
AP912A (en) 2001-12-08
CZ409699A3 (cs) 2000-02-16
HRP980341A2 (en) 1999-02-28
AU8110498A (en) 1999-01-04
EA199900937A1 (ru) 2000-08-28
PT1001813E (pt) 2003-07-31
PL337692A1 (en) 2000-08-28
TW406023B (en) 2000-09-21
HUP0003323A2 (hu) 2001-06-28
DE69814091D1 (de) 2003-06-05
AP9801268A0 (en) 1998-06-30
ES2195355T3 (es) 2003-12-01
IS2004B (is) 2005-04-15
SK282946B6 (sk) 2003-01-09
US6632803B1 (en) 2003-10-14
CA2295035C (en) 2005-04-19
CN1261287A (zh) 2000-07-26
BRPI9809468B8 (pt) 2022-01-18
BG64584B1 (bg) 2005-08-31
ZA985364B (en) 1999-12-20
TR199903191T2 (xx) 2000-09-21
JP2000513029A (ja) 2000-10-03
UY25055A1 (es) 2000-12-29
RS49633B (sr) 2007-08-03
OA11232A (en) 2003-05-26
CN1125653C (zh) 2003-10-29
PA8453201A1 (es) 2000-05-24
CO4940450A1 (es) 2000-07-24
KR20010014006A (ko) 2001-02-26
BR9809468B1 (pt) 2013-11-12
EA001924B1 (ru) 2001-10-22
SA98190159B1 (ar) 2005-12-21
NO313125B1 (no) 2002-08-19
ID22939A (id) 1999-12-16
EP1001813B8 (en) 2014-02-12
DE69814091T2 (de) 2004-01-22
BG103882A (bg) 2000-07-31
MY118151A (en) 2004-09-30
MA26508A1 (fr) 2004-12-20
HU228338B1 (en) 2013-03-28
NO995565D0 (no) 1999-11-12
IL132918A0 (en) 2001-03-19
YU68199A (sh) 2002-06-19
NO995565L (no) 1999-11-30
DZ2523A1 (fr) 2003-02-01
IS5248A (is) 1999-11-15
CZ289570B6 (cs) 2002-02-13
PE84899A1 (es) 1999-09-17
JP5089004B2 (ja) 2012-12-05
ATE238812T1 (de) 2003-05-15
KR100372988B1 (ko) 2003-02-25
HRP980341B1 (en) 2001-12-31
CA2295035A1 (en) 1998-12-30
HUP0003323A3 (en) 2002-01-28
EP1001813B1 (en) 2003-05-02
WO1998058677A1 (en) 1998-12-30
AU724799B2 (en) 2000-09-28
PL191295B1 (pl) 2006-04-28
IL132918A (en) 2001-09-13
HK1027966A1 (en) 2001-02-02
SI1001813T1 (en) 2004-02-29
NZ501066A (en) 2001-01-26
UA57083C2 (uk) 2003-06-16
AR015900A1 (es) 2001-05-30
EP1001813A1 (en) 2000-05-24
SK159399A3 (en) 2000-06-12
DK1001813T3 (da) 2003-07-28
ME00907B (me) 2007-08-03
TNSN98090A1 (fr) 2005-03-15
BR9809468A (pt) 2000-06-20
GB9713149D0 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
EG23910A (en) Pharmaceutical formulations containing voriconazole
SG79255A1 (en) Pharmaceutical formulations
GB9706089D0 (en) Pharmaceutical composition
IL133928A0 (en) Pharmaceutical composition containing peptichemio
GB9717444D0 (en) Pharmaceutical composition
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
GB9717428D0 (en) Pharmaceutical composition
GB9709739D0 (en) Pharmaceutical formulation
GB9717770D0 (en) Pharmaceutical composition
GB2321190B (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
GB9703607D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9813452D0 (en) Pharmaceutical formulations
GB9825117D0 (en) Pharmaceutical formulations
GB9826392D0 (en) Pharmaceutical formulations
GB9828205D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations
GB9807556D0 (en) Pharmaceutical formulations
GB9606372D0 (en) Pharmaceutical formulations
GB9621531D0 (en) Pharmaceutical formulations
GB9710525D0 (en) Pharmaceutical composition